Regulatory News has published 1 story about ADARx Pharmaceuticals on 28 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 28 September 2026.
This page is generated from Regulatory News’ editorial coverage of ADARx Pharmaceuticals. It is not an advertisement.
On the record
- Company
- ADARx Pharmaceuticals, Inc. (Nasdaq: ADRX)
- Headquarters
- San Diego, California
- Founded
- December 2019, by Dr. Zhen Li
- Regulator
- U.S. Food and Drug Administration (onvuzosiran is in Phase 3 testing; no approval yet)
- Latest milestone
- $446.3 million Nasdaq IPO
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
